This presentation took place on Monday, June 17 in Bethesda, MD during the Fifth Annual Biodefense World Summit 2019 and featured Tom Lowery, PhD, chief scientific officer, T2 Biosystems. During the presentation, Dr. Lowery highlighted how rapid, direct-from-blood diagnostics – such as the T2Bacteria®, T2Candida® and T2Resistance™ Panels – can help slow the spread of MDROs and improve patient outcomes. Dr. Lowery also highlighted new data supporting potential future uses of the T2MR® technology for biodefense applications.
During the presentation, Dr. Lowery shared a number of updates on the clinical utility of T2 technology that further prove T2MR’s ability to enable high-sensitivity, blood culture-independent detection of pathogens at ultra-high sensitivity, including:
- T2Bacteria provides actionable clinical information: New, independent T2Bacteria Panel clinical data demonstrates its ability to substantially benefit patients suspected of sepsis in both the emergency department and intensive care unit by providing information that enables significant reductions in time to effective therapy, de-escalation of unnecessary therapy, and avoidance of premature discharges and readmissions to the emergency department.
- T2Candida auris research-use-only provides significantly faster results in detecting the recently emerging superbug, Candida auris: Research data shows that the T2Candida auris RUO Panel can detect all four known clades of Candida auris in 5 hours, compared to 14 days with culture methods.
- T2Lyme clinical performance: T2Lyme clinical accuracy data show T2Lyme has higher accuracy than any of the currently available methods and higher positivity rate than existing PCR methods.
- T2MR Technology can detect five biothreat pathogens: New data show that the T2MR technology can detect five biothreat pathogens, including: Bacillus anthracis (anthrax), Burkholderia spp., Rickettsia prowazekii, Francisella tularensis and Yersinia pestis. These biothreat pathogens can be detected by T2MR technology, which has been proven to work in whole blood (no pre-culture required), environmental samples, other biofluids, and swab samples. The Department of Homeland Security (DHS) has defined these as biothreat pathogens because they require quick antibiotic treatment and can be difficult to diagnose due to non-distinguishing symptoms, making the development and availability of rapid, high-throughput, high sensitivity diagnostics for these biothreat pathogens a national priority.